Scoring system can identify recurrence risk for DCIS breast cancer
A multigene test for predicting risk of breast cancer recurrence represents the first such assay used to differentiate lower-risk ductal carcinoma in situ from more aggressive forms.
Genetic Testing
Genetic variation in ovarian cancer thwarts treatment
Women with a variant of the KRAS oncogene are three times more resistant to platinum chemotherapy, the standard treatment for ovarian cancer, than are women without this variant.
Gene sequencing can match patients to best cancer trials
Identifying the “mutational landscape” of a person’s cancer is a promising method of determining which trials are best-suited to the patient’s particular case.
High rate of leukemia in elderly may be due to stem cell aging
Hematopoietic stem cells from healthy persons older than 65 years make fewer immunoprotective lymphocytes than do stem cells from healthy persons aged 20 to 35 years.
Make genetic testing part of retinoblastoma care
Genetic evaluations by a multidisciplinary health team improved risk prediction for children with retinoblastoma and their relatives, and prevented overuse of clinical screening tests.
Myelodysplasia gene mutation can aid diagnosis
The recent discovery of gene mutations in a genomic study of myelodysplastic syndromes could enable diagnosis using only a blood test rather than a bone marrow biopsy.
CV drug shows promise as a leukemia treatment
A vasodilator that blocks the activity of a protein called Rho kinase (ROCK) may be effective against difficult-to-treat types of leukemia.
Family studies reveal leukemia gene
A genetic defect found on the GATA2 gene predisposes people to acute myeloid leukemia (AML) and myelodysplasia, researchers have learned.
Gene discovery may lead to cure for rare vascular cancer
A specific genetic alteration has been identified as a defining feature of epithelioid hemangioendothelioma (EHE), a vascular sarcoma that strikes about 100 people nationwide each year.
Pemetrexed garners good response in ALK-rearranged lung cancer
Pemetrexed (Alimta) appears to be an effective treatment in persons with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive.
- Loading...
Loading...
Loading... 
Loading...